An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

  • STATUS
    Recruiting
  • End date
    Sep 30, 2026
  • participants needed
    600
  • sponsor
    University of Texas Southwestern Medical Center
Updated on 24 November 2021
cancer
Accepts healthy volunteers

Summary

The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor growth. This study uses specially labeled nutrient tracers of compounds normally found circulating in the blood. The nutrients (glucose, fructose, glutamine, acetate, and lactate) are also found in common foods. A nutrient tracer will be given to the participants through an intravenous (IV) catheter during surgery or biopsy, and blood will be collected every 30 minutes during the infusion to monitor safety parameters and the nutrient tracers. The investigators will collect a tissue sample after the completion of surgery. Participants not having an infusion will have their tissue collected after surgery or biopsy.

Participation in this study will not change patient care. All patients will receive standard of care treatment as determined by their doctors.

Description

The purpose of this study is to understand the metabolism of kidney cancers (renal cell carcinomas and urothelial cell carcinomas involving the kidney) in patients. Metabolism is the term used to describe how cells take up different nutrients and convert them to energy and materials needed for cell growth. In cancer, metabolism is hijacked to support the needs of cancer cells. Cancer cells can use multiple nutrients in the blood to fuel their growth, but it is not known what materials cancer cells make with those nutrients in patients.

Many participants in this study will be infused with a 13C-labeled nutrient during their surgery or biopsy. 13C means that the carbon in the nutrient is heavier than 12C carbons that are the most abundant carbon atoms in nature. 13C carbons account for about 1% of natural carbon atoms are not radioactive or harmful in any way. Using the tissue collected during or after surgery and/or biopsy, the researchers can track how the heavier 13C carbons from the infused nutrient are being used to make different materials that cancer cells need to grow.

The researchers hope to understand how kidney cancers change their metabolism to adapt, grow, and survive in patients. The knowledge learned from this study will be used to support the development of therapies that target metabolic adaptations, and the development of new non-invasive imaging techniques that will improve the care and survival of future kidney cancer patients.

Details
Condition clear cell carcinoma, Malignant neoplasm of kidney, Nephropathy, Succinate Dehydrogenase Deficient Renal Cell Carcinoma, Renal Cancer, stage iv kidney cancer, Metastatic Kidney Cancer, Renal Cell Cancer, Kidney Disease (Pediatric), Urologic Cancer, clear cell renal cell carcinoma, Clear cell adenocarcinoma, Stage IV Renal Cell Cancer, papillary renal cell carcinoma, Malignant Adenoma, prcc, Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma, Transitional cell carcinoma, Metastatic Urothelial Carcinoma, Fumarate Hydratase Deficiency, Urothelial Carcinoma, Kidney Cancer, HLRCC, urinary tract neoplasm, Kidney Disease, cancer, renal, Adenocarcinoma, Hereditary Leiomyomatosis and Renal Cell Cancer
Treatment 13C-glucose, 13C-Acetate, 13C-Lactate, 13C-Glutamine, 13C-Fructose
Clinical Study IdentifierNCT04623502
SponsorUniversity of Texas Southwestern Medical Center
Last Modified on24 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must have radiographic evidence of known or probable kidney or urothelial cancer requiring surgical biopsy or excision
Age 18 years
Subjects of all races and ethnic origins
The willingness to sign and ability to understand a written informed consent
Patients participating in other clinical trials are eligible, and will be evaluated on a case by case basis by the Principal Investigator, Dr. Vitaly Margulis, MD

Exclusion Criteria

Uncontrolled or poorly controlled diabetes for patients receiving a 13C infusion
Pregnant or breastfeeding
Not a surgical candidate
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note